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Abstract: Our understanding of the mechanisms of action of GH and its receptor, the GHR, has advanced significantly in 
the last decade and has provided some important surprises. It is now clear that the GH-GHR axis activates a number of 
inter-related signalling pathways, not all of which are dependent on the intracellular tyrosine kinase, JAK2 as originally 
postulated. JAK2-independent pathways, mediated via the Src family kinases, together with a number of negative 
regulators of GH signalling and emerging cross-talk mechanisms with other growth factor receptors, provide a complex 
array of mechanisms that are capable of fine-tuning responses to GH in a cell context dependent manner. Additionally, it 
is also now clear that GH and the GHR can translocate to the nucleus of target cells and initiate, as yet not well defined, 
nuclear responses. Continued emphasis on elucidation of these complex mechanisms is critical to provide further insights 
into the diverse physiological and pathophysiological effects of GH. 
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INTRODUCTION 
 The growth hormone receptor (GHR) was first 
described/detected in tissues by Tsushima & Friesen in 1973 
on the basis of specific high affinity 
125
I-hGH binding studies 
[1]. Early studies focussed on the functional roles of GH-
GHR interaction, species specificity of binding, regulation of 
GHR expression and relationships with various GH-related 
disorders. With the cloning of the GHR in 1987 by the 
Genentech team [2], evidence has continued to mount 
regarding the structure-function relationships, clinically 
relevant mutations, mechanisms of action, signalling 
pathways and agonists and antagonists for clinical use. 
 Over this time a quite remarkable evolution of the 
functional paradigm has occurred - from GH-induced 
dimerisation to constitutive homodimerisation, JAK-STAT 
specific signalling to additional JAK-independent signalling, 
stand-alone signalling and cross-talk signalling with other 
growth factor receptors, both endocrine and autocrine 
activation, and cell membrane versus nuclear localisation 
and function. Additionally, the identification of the soluble 
extracellular domain - the GH binding protein, GHBP - and 
its potential in prolonging the half life of GH in the 
circulation and/or influencing its action at the target cell have 
provided new understandings in the complexities of GH and 
GHR action. 
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 This review summarises the 2010 state of knowledge 
regarding the mechanism of action of GH through its 
cognate receptor, the GHR. 
GHR STRUCTURE AND FUNCTION 
 The original view of GH-GHR interactions, based on the 
crystal structures of GH bound to the extracellular domain of 
the GHR, was that two GHR molecules were bound by a 
single GH molecule in a sequential, 2-step binding reaction 
[3, 4]. GH, with 2 distinct and asymmetric binding sites on 
opposite faces of the GH molecule, bound with differing 
affinities to a single binding site on each of two GHR 
molecules. The resultant dimerisation of the GHR which, 
like other Class 1 cytokine receptors, does not contain an 
intrinsic kinase domain, then recruited the cytoplasmic 
kinase, JAK 2, to initiate intracellular signalling [5]. More 
recent evidence, however, clearly suggests that the GHR 
exists, in its non-liganded state, as a natural homodimer [6, 
7], each GHR molecule already associated with one or more 
inactive kinases, including JAK2 and Src family kinases, and 
that binding of GH occurs in a 2-step reaction involving 
rotation and re-orientation of the second GHR molecule [8]. 
This leads to activation and cross-phosphorylation of the 
associated kinases, phosphorylation of each GHR 
cytoplasmic tail and the recruitment and subsequent 
phosphorylation of cytoplasmic proteins that then trigger 
further phosphorylation cascades and transcriptional activity 
(for details see below). 
 Precise structural and functional knowledge of GH-GHR 
interaction has led to the development over the past 15 years 
of a variety of GHR functional agonists and antagonists with  
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real or potential application for clinical use [reviewed in 9, 
10]. GH modified by covalent attachment of varying 
amounts of polyethylene glycol (pegylated GH) has led to 
longer half-lives and longer-acting agonists, although with 
reduced potency [reviewed in 10]; fusion proteins between 
GH and the extracellular domain of the GHR (the GHBP) led 
to a markedly prolonged half life of the immunoreactive GH 
but also, intriguingly, to enhance weight gain and circulating 
IGF-I in hypophysectomised rats [11]; a variety of mutations 
within site 1 have demonstrated enhanced receptor potency 
through increased binding affinity ([12,13]; a G120K 
mutation in site 2, coupled with site 1-enhancing mutations 
and pegylation (B2036-PEG, pegvisomant) has led to a 
highly potent antagonist that is now in use for treatment of 
acromegaly [reviewed in 10, 14]. 
 Despite the constitutive dimer structure of the membrane-
inserted GHR, conformational changes elicited by the 2-site 
binding of GH are still required for activation. A GH variant 
in which the second binding site has been mutated (G120R 
GH) abrogates binding at this site, acts as a GH antagonist, 
and fails to activate GHR signalling [15, 16]. Detailed 
structural studies have demonstrated the mechanistic basis 
for this [9, 17]. Surprisingly, however, a G120R-G120R 
linked dimer variant that contains two active site 1 domains, 
but no active site 2 domains, was able to activate GHR 
signalling in a similar dose and time course relationship to 
native GH itself, albeit with diminished potency [18]. This 
suggests that it is not the binding to GH site 2 per se that 
triggers the appropriate activating conformational change but 
that flexibility in the extracellular domain, that allows the 
cooperative binding of a ligand with two GH site 1s, is 
sufficient for GHR activation. 
 The GHR contains a number of structural features that 
define its various activities and characterise it as a distinct 
member of the class 1 cytokine receptor family [reviewed in 
19-21]. The extracellular domain consists of an N-terminal 
fibronectin-like domain, 3 conserved cysteine pairs and a 
conserved WSXWS domain (YXXFS in human GHR) in the 
juxta-membrane extracellular domain which is critical to the 
conformational change following binding of GH. A single 
transmembrane domain is followed by two proline-rich 
regions (so-called Box 1 and Box 2) in the juxta-membrane 
intracellular domain which are required for both JAK2 
association with GHR and subsequent GH-induced JAK2 
activation, respectively. Several tyrosine phosphorylation 
sites in the C-terminal domains represent the activated 
binding sites for a number of cytoplasmic signalling 
molecules that result in GH-induced signalling cascades (see 
below). 
 JAK2 is now also known to stabilise the GHR dimer, 
which initially forms in the endoplasmic reticulum, as it 
translocates through the endoplasmic reticulum and Golgi on 
its way to the plasma membrane [22] (Fig. 1). JAK2 may 
also stabilise the membrane location and decrease the 
constitutive internalisation and down regulation of the GHR 
[23-25]. In contrast, some studies have disagreed as to 
whether GH-induced internalisation of the GHR is [26, 27] 
or is not [28] dependent on JAK activation. The most recent 
study by Deng et al. [29] suggests that GH-induced GHR 
downregulation depends on ubiquitination that requires both 
JAK2 activity and GHR phosphorylation. 
 A number of variant, alternatively-spliced GHR 
transcripts have been reported, although the functional 
implications have not been fully understood. At least 13 
hGHR mRNAs are generated through alternative splicing in 
the 5’ untranslated exons, although all splice into a common 
acceptor site just upstream of the translation start site in exon 
2, thereby each giving rise to a full length receptor. 
Expression levels vary markedly, some are expressed 
widely, others in a developmental and/or tissue specific 
manner [30]. Differential promoter usage leads to variation 
in transcript expression, with the so-called V2 transcript 
being the major ubiquitously expressed form. The 
physiological implications of this developmental and tissue-
specific regulation are not clear. An exon-3 deleted form of 
the GHR has been reported to be widely expressed in human 
tissues [31, 32]. This form which lacks amino acids 7-28 at 
the N-terminus does not affect GHR binding affinity, 
capacity or internalisation rates, but does influence 
sensitivity to GH activation and is associated with enhanced 
responsiveness to GH treatment in children [33, 34]. It also 
predicts an improved response to the antagonist pegvisomant 
in acromegaly [35]. 
 Naturally occurring, membrane-bound but cytoplasmi-
cally-truncated splice variants of the GHR have been 
reported [36, 37] which, although not having a direct 
signalling function, may still form natural long-short 
heterodimers with the full length GHR as demonstrated 
through transfection studies in 293 cells [37]. The truncated 
variants inhibited STAT5 signalling of the full length GHR 
and therefore may play a significant role in modulating the 
functional activity of the wild-type GHR (Fig. 1). The short 
form has also been demonstrated to have a greater tendency 
for proteolytic cleavage of the extracellular domain, thereby 
providing a ready source of the soluble growth hormone 
binding protein (GHBP) [37]. 
THE GROWTH HORMONE BINDING PROTEIN 
(GHBP) 
 The GHBP, produced in primates solely by proteolytic 
cleavage, as opposed to rodents where an alternatively 
spliced complementary mRNA transcript is also produced, 
was first described in rabbit serum [38] but subsequently in 
human and other species by Baumann et al. [39] and 
Herington et al. [40]. This was a surprising finding at the 
time as it was generally thought that unlike the steroid 
hormones and some peptide hormones eg insulin-like growth 
factors (IGFs), protein hormones did not require carriage in 
the circulation by specific binding proteins. Several 
functions have been ascribed to the GHBP. In addition to 
carriage in the circulation and increasing the half-life of GH 
[41], the GHBP clearly has a role in modulating the delivery 
of GH to the GHR within the extracellular environment. In 
this context the soluble, extracellular GHBP could act as a 
competitive inhibitor and sequester GH away from the GHR. 
This has been shown to be the case in vitro in both 3T3-
F442A preadipocytes and in IM-9 lymphocytes [42]. Under 
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the original GH-induced dimer model, it was also suggested 
that the soluble extracellular GHBP could compete with 
monomeric membrane-bound forms of the GHR and 
therefore form (probably) inactive long-short heterodimers, 
that would fail to signal, or at least signal quite differently 
from the wild-type long-long homodimers [43]. With the 
more recent understanding of the intracellular pre-formation 
of GHR dimers, this model is less tenable, although as 
mentioned above the existence of the naturally produced 
membrane-bound truncated splice-variant described by Ross 
et al. [37] may provide the physiological equivalent of the 
variant long-short dimers. Overexpression of the truncated 
form does act as a dominant negative inhibitor of the full-
length GHR [37]. Nonetheless, with the new dimer model 
paradigm the cellular functional role of the GHBP remains 
unclear, although suggestions that it may have a role in the 
nucleus cannot be discarded (see below). 
 Proteolytic cleavage of the membrane-bound GHR has 
been demonstrated to be catalysed by ADAM 17 (or TACE) 
in the proximal membrane region and to release the 
extracellular domain of the receptor in humans and other 
species [44]. Cleavage can be induced by a variety of factors, 
including protein kinase C activators, some growth factors, 
serum or endotoxin [45, 46] and has been reported to 
regulate both GHR sensitivity and signalling [22]. The 
remnant protein (transmembrane plus cytoplasmic domains) 
intriguingly can be subsequently cleaved by gamma-
secretase within the transmembrane domain to release the 
intracellular domain within the cell [47]. This fragment has 
been detected in both the cell cytosol and nucleus [47], 
however it is not know if this fragment has intracellular or 
intranuclear functions via regulation of gene expression (but 
see below). 
GHR SIGNALLING 
 Phosphorylation of the several cytoplasmic domain 
tyrosines following GH activation leads to activation of 
several signalling pathways, many of which are common 
and/or complementary to those of the other recognised Class 
1 cytokine receptor mechanisms of action [48]. The major, 
but not sole, effector of signalling is JAK2 and the main 
JAK2 pathway involved is that of the Signal Transducers 
and Activators of Transcription (STATs). Additionally, 
however, there is considerable evidence now demonstrating 
both JAK2-independent signalling as well as major 
inhibitory mechanisms for regulating GH action and GHR 
signalling through the negative modulators, Suppressors of 
Cytokine Signalling (SOCS) and Protein Tyrosine 
Phosphatases (PTPs). 
JAK2- Dependent Signalling 
 JAK2 is one of four Janus tyrosine kinases [48]. As 
indicated above, binding of GH to the GHR homodimer 
activates the kinase domains of both JAK2 molecules bound 
to the proline-rich Box 1 domains, leading to 
phosphorylation of each JAK2 at multiple tyrosine residues 
[5, 49]. GH-induced phosphorylation of both JAK1 and 3 
has also been reported [50, 51] although this represents a 
minor event. Subsequent cross-phosphorylation of tyrosines 
in the cytoplasmic tails of the two GHR molecules [52] leads 
to recruitment of a host of other cytoplasmic signalling 
intermediates harbouring Src homology 2 (SH2)-domains [ 
 
Fig. (1). Schematic of the role of JAK2 in stabilising the initial formation of the GHR dimer in the endoplasmic reticulum, prior to 
translocation to the plasma membrane. Formation of both the long-long homodimer and the predicted long-short heterodimer variants and 
their impact on GH-induced signal transduction is illustrated. 
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reviewed in detail in 20] (Fig. 2). Recruitment of specific 
mediators may be dependent on cell type, 
compartmentalisation and differentiation stage [eg 53]. The 
transcription factors STAT5 a and b are the key mediators of 
JAK2 activation, although STATs 1 and 3 have also been 
implicated in some signalling pathways [54]. 
 Following phosphorylation of STAT 5a and b, they 
homo- or -heterodimerise, translate to the nucleus and bind 
directly to STAT responsive elements in promoters of target 
genes [54, 55]. The JAK2-STAT 5 pathway has been shown 
to be central to GH-induced changes in metabolic function, 
body growth and IGF-I gene transcription [54-56]. Defects 
in JAK-STAT signalling have been reported to lead to 
growth retardation in human subjects [57, 58]. 
 JAK2 also binds other adaptor proteins independently of 
the STATs (Fig. 2). Binding of Shc to JAK2 leads to 
sequential activation of the Grb2-SOS-Ras/Raf- MAPK 
pathway in which activated ERK1/2 either directly, or via 
phosphorylation of the transcription factors Elk and/or 
CEBPbeta, activates specific sets of target genes [59-61]. 
 GH activation also leads to JAK2-dependent 
phosphorylation of Insulin Receptor Substrate (IRS) proteins 
1, 2 and 3, thus activating the PI-3 kinase/Akt pathway [59, 
62]. GH also results in Focal Adhesion Kinase (FAK) 
activation, leading to a GH-induced reorganisation of the 
actin cytoskeleton in a variety of cell types [63, 64]. FAK 
activation appears to require association with JAK2 as 
demonstrated by use of JAK2 inhibitor AG490 [65], 
although other data suggest the c-Src family of protein 
kinases may also be essential [66]. FAK also can interact 
with the PI3-K/Akt pathway [67] and may provide an 
alternative pathway to IRS stimulated PI3-K/Akt for GH to 
modulate cell activities in cell type and cell differentiation 
specific ways. 
JAK2-Independent Signalling 
 Despite the key role for JAK2 in GHR signalling, 
evidence continues to mount demonstrating a number of 
JAK2-independent signalling mechanisms, particularly using 
Src family kinases. ERK1/2 activation has been 
demonstrated to occur through an alternative JAK2-
independent pathway [68, 69]. GH-induced c-Src, c-Fyn and 
Lyn phosphorylation has been shown to activate a number of 
signalling molecules, including FAK, p130Cas and CrkII - 
all of which are linked to activation of several other key 
pathways via Grb2 or phospholipase C gamma and Ras 
(ERK1/2 pathway), CrkII/Rap1/2 (MAPK/JNK/c-Jun 
pathway) and the Ras-like small GTPases RalA/RalB 
(ERK1/2 via phospholipase D) [reviewed in detail in 20] 
(Fig. 2). 
 Recent data from Rowlinson et al. [70] have shown that 
Lyn may be the major Src kinase involved - transfection with 
Lyn siRNA caused a major decrease in GH-activated ERK. 
That it was independent of JAK2 was shown in 
GHR+ve/JAK2-ve 2A cells. Human GH-stimulated ERK 
activation was blocked by the Src inhibitor, PP2. That Lyn 
 
Fig. (2). A simplified model for the JAK2-dependent and Src (JAK2-independent) signalling pathways initiated by GH interaction at the cell 
membrane. Adapted from [20]. 
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acts directly via phospholipase C was also shown using the 
PLC inhibitor U73122 [70]. In contrast, GH activation of the 
small GTPases Rap1/Rap2 can also negatively impact GH-
stimulated RalA/B and therefore inhibit GH-stimulated 
Erk1/2 and Elk-1 mediated transcription. In combination, 
therefore, GH-activation of Rap 1/2 provides a mechanism 
for “switching” between ERK1/2 and JNK mediated 
activities [20]. 
 The most striking evidence for JAK2 independent 
signalling has come from recent in vivo studies by Barclay et 
al. [71]. They showed, in mice with a mutated JAK2 proline 
rich binding motif in Box 1 of the GHR, that Src and 
ERK1/2 were activated by GH injection but JAK2, STATs 3 
and 5 or Akt were not. The mice had a dwarf phenotype, 
illustrating the key role of JAK2 signalling in growth 
regulation by GH. 
Negative Regulators of GHR Signalling 
 The Suppressors of Cytokine Signalling (SOCS) family 
are negative feedback regulators of cytokine receptor 
signalling. With respect to modulating GH action and GHR 
signalling SOCS1, 2, 3 and CIS (cytokine inducible SH2 
protein) are the key factors involved [reviewed in 72]. Each 
of these SOCs is induced by GH and each can inhibit GHR 
signalling through several mechanisms (Fig. 3):  
A. Direct binding to JAK2, thereby blocking JAK2 
kinase activation (SOCS 1, 2, 3) [73] 
B. Direct binding to phosphorylated tyrosines in the 
GHR (SOCS 2, 3 and CIS) [74, 75], thereby 
competitively inhibiting STAT5b binding (SOCS2, 
CIS). The SOCS3 GHR binding sites are not primary 
STAT5 sites and so it appears that its actions are 
through steric inhibiton of JAK phosphorylation [74]. 
C. Induced proteosomal degradation of GHR through 
increased ubiquitination due to a role as a ubiquitin 
ligase (SOCS 1, 2, CIS) [76]. 
 The effects of SOCS however are complex and vary in 
their relative effectiveness as GHR signalling modulators, 
both in vitro and in vivo. This is reflected in comprehensive 
studies with SOCS knockout mouse models. SOCS1
-/-
 mice 
are contradictorily growth retarded (implying it is a positive 
regulator of GH signalling) [77] and the physiological 
relevance of its in vitro inhibitory effects due to 
overexpression have therefore been questioned. Neither 
SOCS3
-/-
 nor CIS
-/-
 mice demonstrate any growth phenotype 
[72,78], therefore raising the issues of functional redundancy 
across the family. SOCS2
-/-
 mice on the other hand are large, 
signifying that SOCS2 may be the major SOCS involved 
[79]. STAT5b is required for SOCS2
-/-
 gigantism [80]. GH 
deficiency reverses gigantism and GH replacement in GH 
deficient SOCS2
-/-
 demonstrate increased GH sensitivity 
[81]. Interestingly, SOCS2 has also been shown to interact 
with the IGF-I receptor and therefore it may have a major 
coordinating role in growth regulation. 
 The Protein Tyrosine Phosphatases (PTPs) are another 
significant group of negative regulators of GH/GHR 
signalling (Fig. 3D). Three such PTPs have been linked to 
the GHR - SHP-1 (or PTP-1), PTP-1b and PTP-H1 
[reviewed in 72]. SHP-1 is activated by GH and can bind and 
inhibit STAT5b [82]. Both SHP-1and PTP-1b can interact 
directly with JAK2 and regulate dephosphorylation of the 
GH-activated form [83, 84]. PTP1b can also bind directly to 
activated GHR and cause dephosphorylation [85]. PTP-H1 
also binds directly to and inactivates the GH-induced 
phosphorylated GHR, thereby inhibiting recruitment of SH2 
and other cytoplasmic signalling molecules [85]. 
Intriguingly, another PTP, SHP-2, has been reported to be 
both a positive and negative regulator of GHR signalling [86, 
87]. The underlying mechanisms for SHP-2 function have 
not been elucidated. 
 Signal regulatory protein  (SIRP) is a transmembrane 
glycoprotein which is phosphorylated in a JAK2-dependent 
manner and can then associate with at least the PTP SHP-2. 
SIRP can negatively regulate GH-activated signalling [88] 
by inhibiting the phosphorylation of JAK2, STAT5b, STAT3 
and ERK1/2, perhaps by binding to SHP-1 or sequestering 
the GHR positive regulator SHP-2 or JAK2 [86] (Fig. 3E). 
Signalling Crosstalk 
 Evidence is now emerging of significant cross-talk 
between the GHR and other receptor signalling systems. 
 GH-induced phosphorylation of the ErbB family of 
receptors, including the EGFR, has been shown to regulate 
EGF responsiveness [reviewed in 89]. Yamauchi et al. [90] 
have shown that GH, via a JAK2 dependent mechanism, can 
directly tyrosine phosphorylate the EGFR in vivo and in vitro 
and that this was independent of the intrinsic tyrosine kinase 
of the EGFR itself. It led to enhanced binding and activation 
of Grb2 and subsequent activation of ERK1/2. In adipocytes, 
GH also led to EGFR serine/threonine phosphorylation, but 
this was indirect via ERK1/2 [91]. This led to enhanced 
EGF-stimulated ERK and reduced EGF-induced EGFR 
down-regulation, both mechanisms that enhance/prolong the 
effects of EGF. 
 Both GH and insulin are known key mediators of growth 
and metabolic regulation. Both hormones utilise common 
signalling pathways and recent evidence demonstrates that 
they can directly interact and influence each other’s effects 
by signalling cross-talk. As reviewed recently by Xu 
&Messina [92] insulin regulation of GH signalling is 
dependent on the exposure time to insulin - short exposure 
stimulating the GH-activated MAPK pathway downstream 
of the GHR itself, longer exposure having the reverse effect 
and utilising both receptor and downstream mechanisms. In 
contrast long-term high dose GH has an inhibitory effect on 
insulin signalling pathways (IRS-PI3K) and may reflect a 
mechanistic explanation of the induction of insulin 
resistance. 
 The relationship between GH and IGF-1 in mechanisms 
underlying cell proliferation and growth is well known. 
Recent data however suggests a much closer functional 
interaction than previously thought. Studies by Frank et al. 
[93, 94] have indicated that GH can induce formation of a 
functional complex between the GHR, JAK2 and the type 1 
insulin-like growth factor receptor (IGF-1R). Deletion of the 
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IGF-1R in primary osteoblasts reduced GH signalling 
through STAT5 [95]. Additionally, they have demonstrated 
that the GH/STAT5 dependence on IGF-1R is at least 
partially independent of the intrinsic tyrosine kinase activity 
of IGF-1R, or indeed of IGF-1 interaction with the IGF-1R. 
Nonetheless, they propose that IGF may enhance the effects 
of GH through the GHR/JAK2/IGF-1R complex [95]. 
Intriguingly, however, there was no effect on GH-stimulated 
ERK signalling, confirming - as discussed above - the 
capacity for STAT5 independent-JAK2-dependent or 
independent GH/GHR signalling. 
NUCLEAR LOCALISATION AND ACTION OF THE 
GHR 
 While classically regarded as a cell membrane-bound 
receptor, more than 10 years ago it was reported that both the 
full-length GHR and its extracellular domain (the GHBP) 
were also found to be present in the cell nucleus of many 
cells [96, 97]. Nuclear localisation occurred in a GH- and 
STAT5/serum starvation-dependent manner [96, 98] and has 
been associated with rapidly proliferating cells eg liver 
regeneration, in chronic liver disease and tumour cells [96, 
99]. These observations, surprising at the time, do however 
reflect the localisation and action of other membrane-bound 
tyrosine kinase receptors (eg EGFR, FGFR, PRLR [reviewed 
in 99]). 
 Subsequent studies have extended these observations to 
provide insight into the mechanisms of nuclear transport and 
the function of nuclear GHR. The wild-type GHR does not 
contain a classical nuclear localisation signal (NLS) and it 
has been suggested that nuclear localisation of either the full 
length or extra cellular domain depends on association with 
an NLS-containing carrier protein and a “piggy-back” 
mechanism involving importin [100]. Engineering an NLS 
into the GHR increased sensitivity to GH, specifically 
autocrine GH [100] - which is expressed in a number of 
tumour cells and is oncogenic when over-expressed [101, 
102] - and led to increased and constitutive cellular 
proliferation [98]. 
 The GHBP, and by implication the nuclear GHR, has 
been shown to act as a transcription factor - capable of direct 
transactivation in a mammalian -galactosidase reporter 
assay [100, 103]. Affinity chromatography of yeast nuclear 
extracts identified a number of specific GHBP-interacting 
proteins with mammalian homologues, including a 
nucleoporin (Nup145) which may be involved in 
GHR/GHBP nuclear import, the translation regulator EF1a, 
Coactivator activator (CoAA) and the thyroid receptor (TR)-
uncoupling protein. The binding to these proteins had an 
absolute requirement for the second serine in the WSXWS-
related conserved motif [100]. Only the interaction with 
CoAA has been further examined and validated by GST-
pulldown and co-immunoprecipitation assays. Importantly, 
the association occurs only in the presence of GH. 
Overexpression of CoAA in GH-responsive cells leads to a 
specific increased proliferative response to GH. CoAA is a 
known coactivator of a number of nuclear steroid receptors 
and has roles in mRNA splicing regulation [104]. CoAA 
contains several NLS sequences and could therefore also be 
involved in the “piggyback” nuclear translocation via 
importin. Nuclear expression of GHR in cancer cells shows 
an association with the frequent over-expression of CoAA 
[105]. Together these observations suggest a key role for the 
nuclear GHR-CoAA complex in mediating the cancer-
 
Fig. (3). A proposed model for the actions of the negative regulators of GH-GHR action - Suppressors of Cytokine Signalling (SOCS), 
Signal Regulatory Protein  (SIRP), Protein yrosine Phosphatases (PTPs). A) Direct binding to and inhibition of phosphorylation of JAK2 
by SOCs 1, 2, 3. B) Direct binding of SOCS 2, 3 or CIS to phosphorylated tyrosines on the GHR, thereby competitively inhibiting binding of 
STATs. C) SOCs 1, 2 or CIS-induced ubiquitination of the GHR, thereby facilitating proteosomal degradation of the GHR. D) 
Dephosphorylation by PTPs of phosphorylated GHR. Some PTPs are also able to bind directly to and inhibit STATs and JAK2 (not 
illustrated). E) SIRP, a transmembrane glycoprotein, inhibits phosphorylation of JAK2 (and STATs - not illustrated), most likely through an 
interaction with the PTPs. 
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related effects of GH. Surprisingly, additional investigations 
into the transcriptional and other roles of nuclear 
GHR/GHBP have not been published in the past 2 years. 
Much work remains to be done to determine the 
physiological and/or pharmacological implications of this 
novel localisation and function. 
CONCLUSION 
 The diverse and central roles of the GH-GHR axis in 
physiology and pathophysiology have been well recognised 
for a long time, but the complexities of its varied 
mechanisms of action are still emerging. This review has 
provided a broad summary of the GH-GHR signalling 
pathways as now understood and reflects the increasingly 
recognised commonalities amongst Class 1 cytokine receptor 
mechanisms and the cross talk and interaction (direct or 
indirect) between other receptor activation pathways (eg 
EGFR and IGF-1R). The identification, but still limited 
knowledge, of the nuclear localisation and nuclear function 
of the GHR is a clear example of the many surprises that are 
predicted to emerge in the continually changing paradigm of 
GH action. 
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